Filtered By:
Vaccination: Varicella-Zoster Virus Vaccine
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 2051 results found since Jan 2013.
Herpes Zoster Virus Reactivation in a 16 Year Old Female Post COVID-19 Vaccine. Case report and Review of the Literature
CONCLUSION: Varicella zoster virus falls under the family of Herpesviridae, It's characterized by its ability to escape host immune system and remain dormant in ganglionic neurons. Reactivation of the infection will result in herpes zoster manifesting as painful vesicles in a dermatomal distribution. Possible link is the suppression of type-one interferons caused by the mRNA-based vaccine such as COVID-19 vaccines. Yet, potential correlation remains to be demonstrated.PMID:37260797 | PMC:PMC10227837 | DOI:10.5455/medarh.2023.77.146-149
Source: Herpes - June 1, 2023 Category: Infectious Diseases Authors: Sadan Alharbi Mohammed Alsubaie Remah Alzayyat Batool Alattas Hassan AlAhmadi Hanoof Alabdullatif Source Type: research
Combination Therapy for the Treatment of Shingles with an Immunostimulatory Vaccine Virus and Acyclovir
Pharmaceuticals (Basel). 2023 Feb 1;16(2):226. doi: 10.3390/ph16020226.ABSTRACTPractically the entire global population is infected by herpesviruses that establish lifelong latency and can be reactivated. Alpha-herpesviruses, herpes simplex viruses 1 and 2 (HSV-1/HSV-2) and varicella zoster virus (VZV), establish latency in sensory neurons and then reactivate to infect epithelial cells in the mucosa or skin, resulting in a vesicular rash. Licensed antivirals inhibit virus replication, but do not affect latency. On reactivation, VZV causes herpes zoster, also known as shingles. The 76-year-old first author of this paper pub...
Source: Herpes - June 1, 2023 Category: Infectious Diseases Authors: Tibor Bakacs Volker Sandig Imre Kovesdi Source Type: research
A Sample Guideline for Reverse Vaccinology Approach for the Development of Subunit Vaccine Using Varicella Zoster as a Model Disease
Methods Mol Biol. 2023;2673:453-474. doi: 10.1007/978-1-0716-3239-0_30.ABSTRACTFor the development of multi-peptide vaccine, identification of antigenic epitopes is crucial. If it is done using wet lab techniques, the identification process can be time-consuming, laborious, and cost-intensive. In silico tools, on the other hand, enable researchers to predict potential epitopes with little to no cost for further in vivo and in vitro testing. The rapid identification process using in silico tools helps in responding to health emergencies faster. Developing an efficient and high coverage vaccine is one of the ways to reduce m...
Source: Herpes - May 31, 2023 Category: Infectious Diseases Authors: Elif Cireli Levent Çavaş Source Type: research
Comparison of the Immune Effects of an mRNA Vaccine and a Subunit Vaccine against Herpes Zoster Administered by Different Injection Methods
Vaccines (Basel). 2023 May 20;11(5):1003. doi: 10.3390/vaccines11051003.ABSTRACTPrevious studies have shown that the herpes zoster subunit vaccine Shingrix™ performs well in clinical trials. However, the key ingredient in its adjuvant, QS21, is extracted from rare plants in South America, so vaccine production is limited. Compared with subunit vaccines, mRNA vaccines have the advantages of faster production and not requiring adjuvants, but currently, there is no authorized mRNA vaccine for herpes zoster. Therefore, this study focused on herpes zoster subunit and mRNA vaccines. We prepared a herpes zoster mRNA vaccine and...
Source: Herpes - May 27, 2023 Category: Infectious Diseases Authors: Kangyang Lin Han Cao Ning Luan Yunfei Wang Jingping Hu Cunbao Liu Source Type: research
Surveying a Sample of the Spanish Ophthalmologic Community about Vaccination against Herpes Zoster
Vaccines (Basel). 2023 May 5;11(5):952. doi: 10.3390/vaccines11050952.ABSTRACTThere are currently two authorized vaccines against herpes zoster (HZ) that have been shown to be safe and effective in its prevention: Zostavax, a zoster vaccine live (ZVL), and Shingrix, a recombinant zoster Vaccine (RZV). Because ophthalmologists work with vision-threatening complications of zoster, such as herpes zoster ophthalmicus (HZO), they are in a good position to advocate for vaccination. Our aim was to determine the current knowledge among Spanish ophthalmologists about the effectiveness of the available vaccines against HZ. A Google ...
Source: Herpes - May 27, 2023 Category: Infectious Diseases Authors: Alberto S ánchez-Mellado Luis Alcaraz-Clemente Marina Rodr íguez-Calvo-de-Mora Jos é-María Sánchez-González Santiago Ortiz-Perez Carlos Rocha-de-Lossada Source Type: research
Return on Investment (ROI) of Three Vaccination Programmes in Italy: HPV at 12 Years, Herpes Zoster in Adults, and Influenza in the Elderly
The objective of this study is to estimate the ROI of three vaccinations (HPV for adolescents, HZ for adults, and influenza for the elderly) in the Italian context, considering the impact of increasing vaccination coverage based on target objectives of the National Immunization Plan (PNPV) 2017-2019 and accounting for different eligibility criteria of each vaccination. Three separate static cohort models were constructed, including the eligible population for these vaccinations on the basis of the PNPV 2017-2019 and following this population until death (lifetime horizon) or until vaccination waning. Each model compares th...
Source: Herpes - May 27, 2023 Category: Infectious Diseases Authors: Marco Barbieri Sara Boccalini Source Type: research
Comparison of the Immune Effects of an mRNA Vaccine and a Subunit Vaccine against Herpes Zoster Administered by Different Injection Methods
Vaccines (Basel). 2023 May 20;11(5):1003. doi: 10.3390/vaccines11051003.ABSTRACTPrevious studies have shown that the herpes zoster subunit vaccine Shingrix™ performs well in clinical trials. However, the key ingredient in its adjuvant, QS21, is extracted from rare plants in South America, so vaccine production is limited. Compared with subunit vaccines, mRNA vaccines have the advantages of faster production and not requiring adjuvants, but currently, there is no authorized mRNA vaccine for herpes zoster. Therefore, this study focused on herpes zoster subunit and mRNA vaccines. We prepared a herpes zoster mRNA vaccine and...
Source: Herpes - May 27, 2023 Category: Infectious Diseases Authors: Kangyang Lin Han Cao Ning Luan Yunfei Wang Jingping Hu Cunbao Liu Source Type: research
Surveying a Sample of the Spanish Ophthalmologic Community about Vaccination against Herpes Zoster
Vaccines (Basel). 2023 May 5;11(5):952. doi: 10.3390/vaccines11050952.ABSTRACTThere are currently two authorized vaccines against herpes zoster (HZ) that have been shown to be safe and effective in its prevention: Zostavax, a zoster vaccine live (ZVL), and Shingrix, a recombinant zoster Vaccine (RZV). Because ophthalmologists work with vision-threatening complications of zoster, such as herpes zoster ophthalmicus (HZO), they are in a good position to advocate for vaccination. Our aim was to determine the current knowledge among Spanish ophthalmologists about the effectiveness of the available vaccines against HZ. A Google ...
Source: Herpes - May 27, 2023 Category: Infectious Diseases Authors: Alberto S ánchez-Mellado Luis Alcaraz-Clemente Marina Rodr íguez-Calvo-de-Mora Jos é-María Sánchez-González Santiago Ortiz-Perez Carlos Rocha-de-Lossada Source Type: research
Return on Investment (ROI) of Three Vaccination Programmes in Italy: HPV at 12 Years, Herpes Zoster in Adults, and Influenza in the Elderly
The objective of this study is to estimate the ROI of three vaccinations (HPV for adolescents, HZ for adults, and influenza for the elderly) in the Italian context, considering the impact of increasing vaccination coverage based on target objectives of the National Immunization Plan (PNPV) 2017-2019 and accounting for different eligibility criteria of each vaccination. Three separate static cohort models were constructed, including the eligible population for these vaccinations on the basis of the PNPV 2017-2019 and following this population until death (lifetime horizon) or until vaccination waning. Each model compares th...
Source: Herpes - May 27, 2023 Category: Infectious Diseases Authors: Marco Barbieri Sara Boccalini Source Type: research
Can the COVID-19 Vaccine Cause Recrudescence of Herpes Zoster Virus While Taking Antiviral Medication?
Cureus. 2023 Apr 24;15(4):e38040. doi: 10.7759/cureus.38040. eCollection 2023 Apr.ABSTRACTCoronavirus disease 2019 (COVID-19) represents a multisystem disease that has caused a devastating global pandemic. The COVID-19 vaccine produced in response to the pandemic has been effective but can have side effects. One well-established condition is the reactivation of herpes zoster (HZ). Various risk factors increase the risk of HZ reactivation such as age, infections, and immunosuppressed states. HZ can have severe complications, including herpes zoster ophthalmicus and postherpetic neuralgia. Here, we present a unique case wher...
Source: Herpes - May 25, 2023 Category: Infectious Diseases Authors: Ameije Ismaili Stefan Anthony Jessica Clark Source Type: research
Clinical characteristics of SARS-CoV-2 vaccine-related acute appendicitis
CONCLUSION: With the exception of older age, the clinical characteristics of patients presenting with acute appendicitis within 21 days of receiving the SARS-CoV-2 vaccination did not differ from those of patients who presented with acute appendicitis not related to the vaccination. This finding suggests that vaccine-related acute appendicitis is similar to "classic" acute appendicitis.PMID:37225246 | DOI:10.1503/cjs.009322
Source: Herpes - May 24, 2023 Category: Infectious Diseases Authors: Elchanan Quint Ivan Kukeev Itai Hazan Daniel Grupel Oleg Dukhno Anton Osyntsov Gilbert Sebbag Ohad Guetta David Czeiger Source Type: research
The necessity for popularizing varicella-zoster virus vaccine programs worldwide: An age-period-cohort analysis for the Global Burden of Disease study 2019
CONCLUSION: The spatiotemporal trends of VHZ were heterogeneous across countries from 1990 to 2019. The spatiotemporal trend in ASIR is highest in the High sociodemographic index (SDI) region, however the EAPC in ASDR is lowest, in part probably due to VHZ vaccination. Therefore, reducing morbidity and burden strategies such as vaccines programs for the prevention of VHZ should be promoted in those regions with high growth incidence and/or burden, especially for the population after 70 years old.PMID:37224620 | DOI:10.1016/j.jiph.2023.05.016
Source: Herpes - May 24, 2023 Category: Infectious Diseases Authors: Wei Zhang Zhi He Pinhao Li Wen Zeng Jianglong Feng Xian Dong Hongguang Lu Source Type: research
Clinical characteristics of SARS-CoV-2 vaccine-related acute appendicitis
CONCLUSION: With the exception of older age, the clinical characteristics of patients presenting with acute appendicitis within 21 days of receiving the SARS-CoV-2 vaccination did not differ from those of patients who presented with acute appendicitis not related to the vaccination. This finding suggests that vaccine-related acute appendicitis is similar to "classic" acute appendicitis.PMID:37225246 | DOI:10.1503/cjs.009322
Source: Herpes - May 24, 2023 Category: Infectious Diseases Authors: Elchanan Quint Ivan Kukeev Itai Hazan Daniel Grupel Oleg Dukhno Anton Osyntsov Gilbert Sebbag Ohad Guetta David Czeiger Source Type: research
The necessity for popularizing varicella-zoster virus vaccine programs worldwide: An age-period-cohort analysis for the Global Burden of Disease study 2019
CONCLUSION: The spatiotemporal trends of VHZ were heterogeneous across countries from 1990 to 2019. The spatiotemporal trend in ASIR is highest in the High sociodemographic index (SDI) region, however the EAPC in ASDR is lowest, in part probably due to VHZ vaccination. Therefore, reducing morbidity and burden strategies such as vaccines programs for the prevention of VHZ should be promoted in those regions with high growth incidence and/or burden, especially for the population after 70 years old.PMID:37224620 | DOI:10.1016/j.jiph.2023.05.016
Source: Herpes - May 24, 2023 Category: Infectious Diseases Authors: Wei Zhang Zhi He Pinhao Li Wen Zeng Jianglong Feng Xian Dong Hongguang Lu Source Type: research
Clinical characteristics of SARS-CoV-2 vaccine-related acute appendicitis
CONCLUSION: With the exception of older age, the clinical characteristics of patients presenting with acute appendicitis within 21 days of receiving the SARS-CoV-2 vaccination did not differ from those of patients who presented with acute appendicitis not related to the vaccination. This finding suggests that vaccine-related acute appendicitis is similar to "classic" acute appendicitis.PMID:37225246 | DOI:10.1503/cjs.009322
Source: Canadian Journal of Surgery - May 24, 2023 Category: Surgery Authors: Elchanan Quint Ivan Kukeev Itai Hazan Daniel Grupel Oleg Dukhno Anton Osyntsov Gilbert Sebbag Ohad Guetta David Czeiger Source Type: research
